Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein

Leukemia

Volumn 28, Issue 10, 2014, Pages 1993-2004

  Purroy, N ^a   Abrisqueta, P ^a   Carabia, J ^a   Carpio, C ^a   Calpe, E ^a   Palacio, C ^a   Castellvi J ^a   Crespo, M ^a   Bosch, F ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; FLUDARABINE; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CD40 ANTIGEN; CHLORMETHINE DERIVATIVE; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; NAPHTHOQUINONE; SEPANTRONIUM BROMIDE; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 9; VIDARABINE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COCULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; UPREGULATION; ANALOGS AND DERIVATIVES; B LYMPHOCYTE; BONE MARROW CELL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; GENE DELETION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; STROMA CELL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; BONE MARROW CELLS; CELL CYCLE; CELL PROLIFERATION; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DELETION; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NAPHTHOQUINONES; NITROGEN MUSTARD COMPOUNDS; STROMAL CELLS; TOLL-LIKE RECEPTOR 9; VIDARABINE;

EID: 84921728686     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.96     Document Type: Article

References (58)

1. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999; 17: 399-408
2. Dameshek W. Chronic lymphocytic leukemia-an accumulative disease of immunolgically incompetent lymphocytes. Blood 1967; 29(Suppl): 566-584
3. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755-764
4. Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563-574
5. Giné E, Martinez A, Villamor N, Ló pez-Guillermo A, Camos M, Martinez D et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (''accelerated'' chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010; 95: 1526-1533
6. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000; 96: 2655-2663
7. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002; 100: 1795-1801
8. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998; 91: 2387-2396
9. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-2783
10. Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4, CD40L T cells by producing CCL22. Eur J Immunol 2002; 32: 1403-1413
11. Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PEM, Simone R et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011; 117: 5463-5472
12. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009; 114: 4441-4450
13. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008; 14: 2519-2526
14. Bö ttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980-988
15. Pascutti MF, Jak M, Tromp JM, Derks IAM, Remmerswaal EBM, Thijssen R et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 2013; 122: 3010-3019
16. Tretter T, Schuler M, Schneller F, Brass U, Esswein M, Aman MJ et al. Direct cellular interaction with activated CD4() T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro. Cell Immunol 1998; 189: 41-50
17. Willimott S, Baou M, Naresh K, Wagner SD. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol 2007; 138: 721-732
18. Scielzo C, Apollonio B, Scarfò L, Janus A, Muzio M, Ten Hacken E et al. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia 2011; 25: 1760-1767
19. Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP et al. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010; 29: 5071-5082
20. Jahrsdö rfer B, Hartmann G, Racila E, Jackson W, Mühlenhoff L, Meinhardt G et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001; 69: 81-88
21. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 95: 999-1006
22. Fonte E, Apollonio B, Scarfò L, Ranghetti P, Fazi C, Ghia P et al. In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors. Clin Cancer Res 2013; 19: 367-379
23. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006; 18: 609-615
24. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921
25. Marusawa H, Matsuzawa S-I, Welsh K, Zou H, Armstrong R, Tamm I et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003; 22: 2729-2740
26. Altieri DC. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem 2004; 92: 656-663
27. Nakagawa Y, Yamaguchi S, Hasegawa M, Nemoto T, Inoue M, Suzuki K et al. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res 2004; 28: 487-494
28. Sachanas S, Levidou G, Angelopoulou MK, Moschogiannis M, Yiakoumis X, Kalpadakis C et al. Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia. Leuk Lymphoma 2013
29. Grzybowska-Izydorczyk O, Cebula B, Robak T, Smolewski P. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer 2010; 46: 800-810
30. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 2011; 102: 614-621
31. Tang H, Shao H, Yu C, Hou J. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. Biochem Pharmacol 2011; 82: 1066-1072
32. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021
33. Tyner JW, Jemal AM, Thayer M, Druker BJ, Chang BH. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia 2012; 26: 623-632
34. Feng W, Yoshida A, Ueda T. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun 2013; 435: 52-57
35. Kaneko N, Kita A, Yamanaka K, Mori M. Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma. Leuk Res 2013; 37: 1156-1161
36. Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC et al. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. Blood 2013; 121: 2029-2037
37. Kita A, Mitsuoka K, Kaneko N, Nakata M, Yamanaka K, Jitsuoka M et al. Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab. J Pharmacol Exp Ther 2012; 343: 178-183
38. Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012; 118: 3128-3134
39. Papadopoulos KP, Smith SE, Steinberg J, Papa R, Lopez-Jimenez J, Keating A et al. A phase II study of sepantronium bromide (YM155) plus rituximab in previously treated subjects with aggressive CD20-positive B cell non-Hodgkin's lymphoma who are ineligible for or have previously received an autologous stem cell transplant. Stage I results. Blood 2012; 120: abstract 2731
40. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castrationresistant taxane-pretreated prostate cancer. Ann Oncol 2012; 23: 968-973
41. Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E et al. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2013; 24: 2601-2606
42. Calissano C, Damle RN, Marsilio S, Yan X-J, Yancopoulos S, Hayes G et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med 2011; 17: 1374-1382
43. Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446
44. MacPhail SH, Banáth JP, Yu TY, Chu EHM, Lambur H, Olive PL. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol 2003; 79: 351-358
45. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007; 21: 110-120
46. Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL, Newton DL. The ''survivin suppressants'' NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol 2012; 70: 207-212
47. Foster ER, Downs JA. Histone H2A phosphorylation in DNA double-strand break repair. FEBS J 2005; 272: 3231-3240
48. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008; 18: 134-147
49. Huang YT, Cheng CC, Lin TC, Chiu TH, Lai PC. Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells. Oncol Rep 2014; 31: 771-780
50. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003; 123: 380-388
51. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003; 116: 2987-2998
52. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99: 4349-4354
53. Morgillo F, Woo JK, Kim ES, Hong WK, Lee H-Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66: 10100-10111
54. Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29-35
55. Sato A, Ito K, Asano T, Sumitomo M, Asano T, Hayakawa M. Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake. Int J Oncol 2007; 30: 695-700
56. Li B, Fan J, Liu X, Qi R, Bo L, Gu J et al. Suppression of colorectal tumor growth by regulated survivin targeting. J Mol Med (Berl) 2006; 84: 1077-1086
57. Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008; 14: 6496-6504
58. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; 344(Pt 2): 305-311.